Seth Klarman Pitches Syneron Medical (ELOS)
Posted: August 11th, 2007 | Author: Stock Pitcher | Filed under: Growth Story, Gurus | No Comments »Not a new position for Seth Klarman of Baupost Group but a postion worth noting especially since Jim Cramer of Mad Money just interviewed the CEO and mentioned the stock a few times the last few weeks so we’re going to dive into the world of Seth Klarman and why he would put 5% of Syneron Medical in his fund that has returned 20% since inception.
After receiving his MBA from Harvard in 1982, Klarman start Baupost with $27 Million in investments but now he has over 5 billion in management. He got his BA from Cornell. According to a BusinessWeek profile of him in August of 2006, since then Klarman has returned 6,133% net of fees. His investing philosophy is centered on value and risk averse techniques which I think is not used enough except for the great Mr. Buffet. His emphasis is that investors are naive to look for returns which is the positive and never look at the risk. We all think yes Apple will go to $180 but we never think hey it could go to $80 instead.
“Margin of Safety: Risk-Averse Value Investing Strategies for the Thoughtful Investor” a book he publish in 1991 increased his notoriety along with his great returns among investors and academia. Since the book is no longer in print, it actually is a much desired item that goes for between $700 to $1200 on Amazon and Ebay. The book is such a collector’s items that many library either protect it or has gotten it stolen. I wish I could get my hands on it. I may track it down one day while the librarian watches me.
This value investor has in his great portfolio, Syneron Medical Ltd., an Israeli maker of aesthetic medical devices which provide cosmestic laser surgery and other cosmestic procedures. Last earnings were decent, Syneron earned $10.3 million, or 37 cents per share, up 16 percent from $8.9 million, or 32 cents per share, in the same period a year ago while revenue rose 36 percent to $37.5 million from $27.5 million. It matched analyst earnings of 37 cents while beating analyst estimates of sales of $33.2 by 13%. Not too shabby I say.
Also better news is that the company boost expectations of sales for this year to $146 million, up 25 percent from the prior year topping forecast of only 20% revenue growth. On earnings day, it rose to $25 but now as I write with the market downturn, it’s $23.56 trading at a PE of 16 and forward PE of 12. No debt. 93 million in cash. AValue? Yes. Growth?
Growth? Yes. It’s growth at 20 plus percent and with a Price to Earning’s Growth PEG at 0.94 is awesome. Recently they got approval for the Vela platform that removes that cellulite from the back of women…well men too..legs. It’s approved by the U.S. Food and Drug Administration and the European Union. Is America become more self conscious? Yes. Is America become more over weight? Yes. Baby boomers want to wear shorts? Of course, especially if they move to Las Vegas or Arizona. So Seth Klarman sees a decent trend and bought it for value. But it’s a growth play too.